Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN

In this study, we have assessed the activation of the cannabinoid CB2 receptor (CB2-R) in a model of mouse myocardial ischemia/reperfusion (I/R). The results show that treatment of animals with WIN55212-2, a CB1/CB2-R agonist, given 30 min before induction of I/R, significantly reduced the extent of infarct size (IS) in the area at risk, as measured 2.5 h later, with almost a 51% inhibition observed at the dose tested of 3.5 mg/kg intraperitoneally (i.p.). The protective effect of WIN55212-2 was almost abolished by the selective CB2-R antagonist AM630 (1 mg/kg i.p.) and not affected by the selective CB1-R antagonist AM251 (3 mg/kg i.p.). The CB2-R antagonist administered alone produced a slight but significant (P<0.05) increase in IS compared with vehicle alone. The protection afforded by WIN55212-2 was paralleled by lower values of myeloperoxidase activity and interleukin-1beta and of the CXC chemokine ligand 8 into the injured tissue. In conclusion, we demonstrate for the first time that exogenous and endogenous CB2-R activation reduces the leukocyte-dependent myocardial damage associated with an I/R procedure.     

Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia

The role of endocannabinoid signaling in the response of the brain to injury is tantalizing but not clear. In this study, transient middle cerebral artery occlusion (MCAo) was used to produce ischemia/reperfusion injury. Brain content of N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol were determined during MCAo. Whole brain AEA content was significantly increased after 30, 60 and 120 min MCAo compared with sham-operated brain. The increase in AEA was localized to the ischemic hemisphere after 30 min MCAo, but at 60 and 120 min, was also increased in the contralateral hemisphere. 2-Arachidonoylglycerol content was unaffected by MCAo. In a second set of studies, injury was assessed 24 h after 2 h MCAo. Rats administered a single dose (3 mg/kg) of the cannabinoid receptor type 1 (CB1) receptor antagonist SR141716 prior to MCAo exhibited a 50% reduction in infarct volume and a 40% improvement in neurological function compared with vehicle control. A second CB1 receptor antagonist, LY320135 (6 mg/kg), also significantly improved neurological function. The CB1 receptor agonist, WIN 55212-2 (0.1-1 mg/kg) did not affect either infarct volume or neurological score.     

High-cholesterol feeding aggravates cerebral infarction via decreasing the CB1 receptor

We examined how feeding conditions affect the CB1 receptor and cerebral infarction caused by cerebral ischemia. Mice were divided into the following three groups: normal diet (ND), caloric restriction (CR) and high-cholesterol-enriched diet (HCD), and were kept for 6 weeks. After 6 weeks, we measured both serum and brain cholesterol and the expression level of cannabinoid CB1 receptor within the brain in intact mice. In addition, middle cerebral artery (MCA) was occluded for 2 h following reperfusion. Serum cholesterol significantly increased in the HCD group in comparison with both the ND and CR groups. However, brain cholesterol decreased in the HCD group. Then, the expression level of CB1 receptor significantly decreased in the HCD group, while that of the CR group clearly increased in comparison with the ND group in intact mice. In MCA-occluded mice, The HCD group produced the most severe cerebral infarction, while cerebral infarction was significantly decreased in the CR group. These results suggest that CR prevents infarction by increasing CB1 receptor expression, while high-cholesterol feeding aggravates cerebral infarction both by hypercholesterolemia in serum and by decreasing CB1 receptor expression modulated by hypocholesterolemia within the brain.     

A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice

Cerebral ischemia induces Ca(2+) influx into neuronal cells, and activates several proteases including calpains. Since calpains play important roles in neuronal cell death, calpain inhibitors may have potential as drugs for cerebral infarction. ((1S)-1((((1S)-1-Benzyl-3- cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945) is a novel calpain inhibitor that has good membrane permeability and water solubility. We evaluated the effect of SNJ-1945 on the focal brain ischemia induced by middle cerebral artery occlusion (MCAO) in mice. Brain damage was evaluated by assessing neurological deficits at 24 h or 72 h after MCAO and also by examining 2,3,5-triphenyltetrazolium chloride (TTC) staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining of brain sections. When injected at 1 h after MCAO, SNJ-1945 at 30 and 100 mg/kg, i.p. decreased the infarction volume and improved the neurological deficits each assessed at 24 h. SNJ-1945 at 100 mg/kg, i.p. also showed neuroprotective effects at 72 h and reduced the number of TUNEL-positive cells at 24 h. SNJ-1945 was able to prevent neuronal cell death even when it was injected at up to 6 h, but not at 8 h, after MCAO. In addition, SNJ-1945 decreased cleaved alpha-spectrin at 6 h and 12 h, and active caspase-3 at 12 h and 24 h in ischemic brain hemisphere. These findings indicate that SNJ-1945 inhibits the activation of calpain, and offers neuroprotection against the effects of acute cerebral ischemia in mice even when given up to 6 h after MCAO. SNJ-1945 may therefore be a potential drug for stroke.     

Role of cannabinoid receptors in the regulation of cardiac contractility during ischemia/reperfusion

We studied the effect of selective ligands of cannabinoid (CB) receptors on contractility of isolated Langendorff-perfused rat heart under conditions of 45-min total ischemia and 30-min reperfusion. Perfusion with a solution containing selective CB receptor agonist HU-210 for 10 min before ischemia increased the severity of reperfusion contractile dysfunction. This drug decreased left ventricular developed pressure and maximum rates of contraction and relaxation, but had no effect on heart rate and end-diastolic pressure. The negative inotropic effect of the drug was transitory and disappeared after 5-min reperfusion. Pretreatment with selective CB1 receptor antagonist SR141716A and selective CB2 receptor antagonist SR144528 had no effect on heart rate and myocardial contractility during reperfusion. Our results indicate that stimulation of CB receptors can increase the degree of reperfusion-induced cardiac contractile dysfunction. However, endogenous cannabinoids are not involved in the development of myocardial contractile dysfunction during ischemia/reperfusion of the isolated heart. __________ Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 142, No. 11, pp. 500–504, November, 2006     

Tacrolimus (FK506) attenuates biphasic cytochrome c release and Bad phosphorylation following transient cerebral ischemia in mice

Tacrolimus (FK506) has a neuroprotective action on cerebral infarction produced by cerebral ischemia, however, detailed mechanisms underlying this action have not been fully elucidated. We examined temporal profiles of survival-and death-related signals, Bad phosphorylation, release of cytochrome c (cyt.c), activation of caspase 3 and DNA fragmentation in the brain during and after middle cerebral artery occlusion (MCAo) in mice, and then examined the effect of tacrolimus on these signals. C57BL/6J mice were subjected to transient MCAo by intraluminal suture insertion for 60 min. Tacrolimus (1 mg/kg, i.p.) was administered immediately after MCAo. There were biphasic increases in the release of cyt.c in the ischemic core and penumbra; with the first increase toward the end of the occlusion period and the second increase 3-12 h after reperfusion. Tacrolimus significantly inhibited the increase of cytosolic cyt.c during ischemia and reperfusion. Phosphorylated Bad, Ser-136 (P-Bad(136)) and Ser-155 (P-Bad(155)) were detected 30 min after MCAo and after reperfusion in the ischemic cortex, respectively. Tacrolimus increased P-Bad(136) during ischemia and prolonged P-Bad(155) expression after reperfusion. Tacrolimus also decreased caspase-3 and terminal deoxynucleotidyl transferase-mediated DNA nick-end labeling-positive cells, and reduced the size of infarct 24 h after reperfusion. Our study provided the first evidence that the neuroprotective action of tacrolimus involved inhibition of biphasic cyt.c release from mitochondria, possibly via up-regulation of Bad phosphorylation at different sites after focal cerebral ischemia and reperfusion.     

糖尿病大鼠 局灶脑缺血／再灌注损伤与脑组织TGF—β1mRNA表达

目的：观察糖尿病和对照组鼠脑缺血/再灌注损伤与转化生长因子β1（TGF-β1）mRNA表达的异质性。方法：采用逆转录聚合酶链式反应（RT-PCR）检测大鼠中脑动脉阻塞（MCAO）后脑内TGF-β1mRNA表达水平,并且应用组织病理进行损伤程度评定。结果：糖尿病组大鼠脑缺血及缺血/再灌损伤程度明显重于“相应对照组”。糖尿病及对照组大鼠在MCAO2h时TGF-β1mRNA表达量明显增高,后者增高比前者更为明显。再灌24h后TGF-β1mRNA表达量下降,但仍高于假手术组。结论：糖尿病加重缺血/再灌性脑损伤;MCAO后TGF-β1mRNA表达增高可能有是机体一种抗损伤反应,糖尿病组抗损伤反应下降。     

缓激肽受体抑制剂对脑缺血再灌注大鼠的脑保护作用

为了探讨缓激肽及其受体在脑缺血急性期对血脑屏障通透性及炎症因子分泌的影响,本研究采用线栓法制作大鼠大脑中动脉梗塞(MCAO)模型,分别应用缓激肽B1和B2受体的特异性抑制剂,在缺血再灌流后24h进行动物行为学评分,TTC染色计算梗死体积,伊文斯蓝染色检测血脑屏障通透性,透射电镜观测血脑屏障超微结构的变化,ELISA对缺血区IL-1β、TNF-α、PGE2进行测定。结果显示:缓激肽B1和B2受体抑制剂能够改善脑缺血大鼠急性期行为学评分、缩小梗死体积、降低血脑屏障通透性、维持血脑屏障结构完整、抑制炎症因子分泌,缓激肽B2受体抑制剂的上述效果优于B1受体抑制剂。以上结果提示缓激肽在脑缺血急性期可以加重脑损伤,其受体的特异性抑制剂可以减轻脑损伤。     

Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons

At present, little is known about the mechanisms by which cannabinoids exert their effects on the central nervous system. In this study, fluorescence imaging and electrophysiological techniques were used to investigate the functional relationship between cell surface cannabinoid type 1 (CB(1)) receptors and GABAergic synaptic transmission in cultured hippocampal neurons. CB(1) receptors were labelled on living neurons using a polyclonal antibody directed against the N-terminal 77 amino acid residues of the rat cloned CB(1) receptor. Highly punctate CB(1) receptor labelling was observed on fine axons and at axonal growth cones, with little somatic labelling. The majority of these sites were associated with synaptic terminals, identified either with immunohistochemical markers or by using the styryl dye FM1-43 to label synaptic vesicles that had undergone active turnover. Dual labelling of neurons for CB(1) receptors with either the inhibitory neurotransmitter GABA or its synthesising enzyme glutamate decarboxylase, demonstrated a strong correspondence. The immunocytochemical data was supported by functional studies using whole-cell patch-clamp recordings of miniature inhibitory postsynaptic currents (mIPSCs). The cannabinoid agonist WIN55,212-2 (100nM) markedly inhibited (by 77+/-6.3%) the frequency of pharmacologically-isolated GABAergic mIPSCs. The effects of WIN55,212-2 were blocked in the presence of the selective CB(1) receptor antagonist SR141716A (100nM).In conclusion, the present data show that cell surface CB(1) receptors are expressed at presynaptic GABAergic terminals, where their activation inhibits GABA release. Their presence on growth cones could indicate a role in the targeting of inhibitory connections during development.     

Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion

Stroke is a leading cause of death and disability but has limited therapeutic options. Thiazolidinediones (TZDs), agonists for the nuclear receptor, peroxisome proliferator-activated receptor (PPAR)γ, reduce infarct volume and improve neurologic function following transient middle cerebral artery occlusion (MCAO) in rats. Translation of these findings into clinical therapy will require careful assessment of dosing paradigms and effective time windows for treatment. Understanding the mechanisms by which TZDs protect the brain provides insight into how time windows for neuroprotection might be extended. We find that two TZDs, pioglitazone and rosiglitazone, significantly reduce infarct volume at doses similar to those used clinically (1 mg/kg for pioglitazone and 0.1 mg/kg for rosiglitazone). We also find that pioglitazone reduces infarction volume in a transient, but not a permanent MCAO model suggesting that reperfusion plays an important role in TZD mediated neuroprotection. Since PPARγ agonists reduce inflammation and oxidative stress, both of which are exacerbated by reperfusion, we hypothesized that TZDs would be most effective if administered prior to reperfusion. We administered TZDs 3 h after MCAO and found that infarction volume and neurologic function are significantly improved in animals reperfused at 3 h and 15 min (after TZD treatment), but not in animals reperfused at 2 h (before TZD treatment) when assessed either 24 h or 3 weeks after MCAO. While TZDs reduce intercellular adhesion molecule (ICAM) expression to a similar extent regardless of the time of reperfusion, leukocyte entry into brain parenchyma is more dramatically reduced when reperfusion is delayed until after drug treatment. The finding that delaying reperfusion until after TZD treatment is beneficial despite a longer period of ischemia, is dramatic given the widely held view that duration of ischemia is the most important determinate of injury.     

Bone marrow stromal cells can be delivered to the site of traumatic brain injury via intrathecal transplantation in rabbits

Bis(7)-tacrine, a promising anti-Alzheimer's dimer, has been shown to have multiple neuroprotective activities in vitro. Here, we investigate whether bis(7)-tacrine attenuates focal cerebral ischemic impairment in vivo. Cerebral ischemia was induced in Sprague-Dawley rats by transient (2h) middle cerebral artery occlusion (MCAO) followed by 24h of reperfusion. Bis(7)-tacrine administered intraperitoneally 15 min after ischemia dose-dependently improved neurological behavior deficits and reduced both cerebral infarct volume and edema. The TUNEL staining assay showed that bis(7)-tacrine attenuated neuronal apoptosis in the penumbral region. Compared with that for memantine, a moderately effective N-methyl-d-aspartate (NMDA) receptor antagonist with a similar affinity and potency to bis(7)-tacrine in blocking NMDA receptors, the therapeutic window for bis(7)-tacrine was wider and lasted up to 6h after the onset of ischemia. Bis(7)-tacrine did not affect physiological parameters or regional cerebral blood flow during either the occlusion period or the early reperfusion stage. In conclusion, bis(7)-tacrine dose- and time-dependently protected against acute focal cerebral ischemic insults, possibly through the drug's anti-apoptotic effects during multiple events in the ischemic cascade.     

Neanthes japonica (Iznka) fibrinolytic enzyme reduced cerebral infarction,cerebral edema and increased antioxidation in rat models of focal cerebral ischemia

Thrombolytic agent is increasingly being used in treating acute ischemic stroke. A novel protease with strong thrombolytic activity, Neanthes japonica (Iznka) fibrinolytic enzyme (NJF) discovered in our laboratory has been reported with characteristics of direct hydrolyzing fibrin and fibrinogen. The neuroprotective effect of NJF and urokinase (UK) was tested in rat models of middle cerebral artery occlusion (MCAO). The model was successfully produced by introducing an intraluminal suture into the left middle cerebral artery (MCA). NJF (0.25, 0.5, 1 mg/kg) was injected intravenously 1 h after the onset of reperfusion. Compared with vehicle group, MCAO animals treated with NJF showed dose dependent reduction in cerebral infarction with improved neurological outcome. Meanwhile, ischemia induced cerebral edema was reduced in a dose dependent manner. Treatment with NJF at 0.5 mg/kg was almost equivalent to UK at 15,000 U/kg dosage in the reduction of cerebral infarction and cerebral edema. Biomedical assay showed that NJF treatment suppressed lipid peroxidation and restored superoxide dismutase (SOD) activities in brain tissue. These results suggest that NJF posses neuroprotective potential in rat MCAO and reperfusion model. Neuroprotection shown by NJF may be attributed to inhibition of lipid peroxidation, increase in endogenous antioxidant defense enzymes.     

大鼠脑缺血再灌流后基质金属蛋白酶-2和9的表达

目的：探讨大鼠局灶性脑缺血再灌流后基质金属蛋白酶(MMP)-2和-9(MMP-9)表达的变化规律与脑水肿的关系。方法：用线栓法制作大鼠左侧大脑中动脉阻塞再灌流模型(MCAO),用免疫组化技术分别观察脑缺血再灌流不同时间点MMP-2和MMP-9的表达。结果：(1)脑缺血再灌流后24h可见MMP-2阳性细胞开始出现,3～7d时阳性细胞数达高峰,显色最深,至14d时仍有表达,略高于假手术组。(2)脑缺血再灌流后6h缺血区内MMP-9阳性细胞开始出现,12h明显增高,至2d达高峰,3d后阳性细胞数开始减少,至14d时恢复到基础水平,各相邻时间点比较差异显著。结论：脑缺血再灌流后,病变区MMP-2和MMP-9表达增加,二者在脑缺血再灌流后脑水肿方面起重要作用。     

The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex.

The effects of the selective adenosine A2 receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamido adenosine hydrochloride (CGS 21680) on aspartate and glutamate release from the ischemic rat cerebral cortex were studied with the cortical cup technique. Cerebral ischemia (20 min) was elicited by four vessel occlusion. Pretreatment with CGS 21680 failed to alter basal excitatory amino acid levels, however, CGS 21680 at 10(-6) M significantly enhanced the ischemia-evoked release. Thus, aspartate and glutamate release during ischemia can be stimulated via the activation of A2 receptors, in addition to the suppression of excitatory amino acid release mediated by selective A1 receptor agonists.     

缺血后适应对大鼠脑缺血/再灌注损伤的影响

目的：探讨缺血后适应对大鼠脑缺血/再灌注损伤的影响。方法:应用线栓法制作大鼠脑缺血/再灌注损伤模型；21只雄性SD大鼠随机分为缺血/再灌注组、夹闭单侧颈总动脉后处理组和夹闭双侧颈总动脉后处理组，每组7只。再灌注48 h，测定脑梗死体积；拔栓后1 h及处死大鼠前进行神经功能测定；梗死即刻、梗死后10 min、术中1 h、拔栓后即刻、每次夹/松颈总动脉时、干预后30 min等15个时点监测脑血流。结果:夹闭单侧、双侧颈总动脉后处理组大鼠脑组织梗死体积与缺血/再灌注组相比明显减小，有显著差异；3组脑血流各个时点方差分析差异无显著，但是夹闭双侧颈总动脉后处理组干预30 min后脑血流百分比较缺血/再灌注组、夹闭单侧颈总动脉后处理组降低9％。手术后1 h 3组神经功能评分P<0.05，差异显著，夹闭单侧、双侧颈总动脉后处理组神经功能缺损均比缺血/再灌注组减轻。结论:缺血后适应能够明显减小梗塞体积，改善大鼠术后1h神经功能评分，可能与缺血后适应调节早期再灌注时血流动力学状态有关。     

神经调节素治疗小鼠脑缺血再灌注损伤的机制(英)

目的：研究神经调节素-1β(NRG-1β)对小鼠脑缺血再灌注后神经行为功能、脑geng梗死体积、脑组织含水量、神经细胞凋亡以及胶质细胞水通道蛋白-4（AQP-4）表达的影响和神经保护作用机制。 方法:应用线栓法建立小鼠大脑中动脉闭塞再灌注（MCAO/R）模型,经颈内动脉微量注射NRG-1β(2 μg/kg) 干预治疗,Bederson法评价动物的神经行为功能,氯化三苯基四氮唑（TTC）染色观察脑梗死体积,干湿重法测定脑组织含水量,免疫荧光染色检测神经细胞凋亡,免疫组织化学检测AQP-4的表达。结果:脑缺血再灌注损伤后,动物均表现神经行为功能障碍,缺血侧出现脑梗塞病灶,脑组织含水量、神经细胞凋亡数量和胶质细胞AQP-4表达均高于假手术对照组。与MCAO/R组相比较,MCAO/R+NRG-1β治疗组缺血24h动物神经行为功能损伤明显改善、凋亡神经细胞数明显减少、脑梗塞体积显著缩小,P<0.05;但脑组织含水量和AQP-4表达与MCAO/R组比较无显著差异,P>0.05。缺血再灌注22 h、46 h和70 h组,上述5项指标较相应的MCAO/R组均有显著差异,P<0.05。结论:NRG-1β可能通过下调脑缺血再灌注损伤诱导的胶质细胞AQP-4表达和抑制细胞凋亡,以减轻脑水肿和缩小梗死体积,从而改善动物的神经行为功能。     

他米巴罗汀减轻大鼠脑缺血再灌注损伤

目的探讨他米巴罗汀(Am80)对大鼠脑缺血再灌注损伤(CIR)的作用。方法将大鼠随机分为:假手术组(sham)、模型组(I/R)和他米巴罗汀干预组(Am80,灌胃给予Am80 6 mg/kg)。采用线栓法建立大脑中动脉栓塞(MCAO)模型。术后24 h断头取脑,在处死前采用双盲法进行神经行为学评分;TTC染色测定脑梗死体积;Western blot和RT-q PCR法分别检测RARα、Bcl-2和Bax蛋白及mRNA的表达。结果 Am80可显著改善MCAO大鼠神经功能缺损,有效地降低脑梗死体积(P0.01),上调RARα和Bcl-2表达(P0.01),降低Bax的表达(P0.01)。结论他米巴罗汀对脑缺血再灌注损伤大鼠有保护作用,其作用可能与抗凋亡有关。     

咪唑安定对脑缺血/再灌注大鼠顶叶碱性成纤维细胞生长因子表达的调节作用

目的观察咪唑安定对大鼠脑局灶性缺血/再灌注脑组织碱性成纤维细胞生长因子(bFGF)表达水平的影响,从而探讨咪唑安定对脑缺血的作用机制。方法采用可逆性大脑中动脉缺血再灌注模型,再灌注同时腹腔注射咪唑安定50 mg.kg-1,再灌注6 h、24 h后断头取脑。观察大鼠梗死体积的变化,用免疫组织化学方法及W estern-b lot方法观察缺血区bFGF的表达,并进行显微图像分析。结果顶叶缺血区周围组织可见bFGF阳性表达产物,正常大鼠未见bFGF阳性表达产物,咪唑安定组与生理盐水组(NS)相比梗死灶体积缩小,免疫组化结果显示咪唑安定组脑缺血灶周围bFGF的平均光密度值高于NS组(P<0.05),阳性细胞主要以神经元、神经胶质细胞为主。W estern-b lot结果表明咪唑安定组整合光密度值与β-actin比值显著高于NS组(P<0.05)。结论咪唑安定对脑缺血性损伤的恢复作用可能与提高缺血周围区bFGF的表达有关。     

阿托伐他汀对大鼠缺血再灌注脑组织中NADPH氧化酶源性超氧阴离子的抑制作用

目的：脑组织在缺血再灌注的早期，超氧阴离子的大量生成加重了脑组织损伤，本实验研究阿托伐他汀对缺血再灌注脑组织保护作用的可能机制。方法:成年雄性Sprague-Dawley大鼠经线栓法阻断大脑中动脉建立脑缺血再灌注模型，再灌注前经腹腔给予阿托伐他汀（立普妥）治疗。脑梗死灶体积用四唑氮蓝染色后测量；NADPH氧化酶酶活性和超氧阴离子水平使用光泽精增强化学发光法定量测定；NADPH氧化酶膜亚基gp91phox、膜易位亚基p47phox和小GTP酶Rac-1蛋白的表达用蛋白质印迹分析。结果:缺血半暗区的NADPH氧化酶活性和超氧阴离子水平增高，于再灌注2 h达到高峰，但缺血中心区的NADPH氧化酶活性和超氧阴离子水平无明显增高。阿托伐他汀预治疗能抑制再灌注2 h后缺血半暗区的NADPH氧化酶活性和超氧阴离子增高，减少膜亚基gp91phox蛋白的表达和预防细胞质亚基p47phox蛋白易位至细胞膜。结论:阿托伐他汀对缺血再灌注脑组织NADPH氧化酶源性超氧阴离子的抑制作用，是其脑保护作用机制之一。     

rhAng-1通过PKCα/MLC通路影响局灶性脑缺血再灌注大鼠血脑屏障通透性

目的研究重组人血管生成素1(rhAng-1)对局灶性脑缺血再灌注大鼠血脑屏障内皮细胞骨架的影响。方法大鼠随机分8组:(1)假手术组;(2)缺血组;(3-5)生理盐水+缺血再灌注12h/48h/7d组;(6-8)Ang-1+缺血再灌注12h/48h/7d组。用伊文思兰渗透性实验检测血脑屏障通透性;Westernblot法检测微血管内皮细胞PKCα和p-MLC的表达。结果 Ang-1可明显降低局灶性脑缺血再灌注大鼠血脑屏障通透性,可使脑微血管内皮细胞PKCα和p-MLC表达水平减少。结论 Ang-1降低血脑屏障通透性与降低PKCα/MLC通路表达相关。